Revised forecast
Fiscal year ending March 2027 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
The forecast incorporates expected growth in Enhertu and Datroway sales and an increase in gross profit from an improvement in the cost-of-sales ratio, as well as higher expenses due to increased profit-share payments to AstraZeneca and other factors, core and non-core income and expenses, finance income and expenses, income taxes and other taxes, and profit for the year attributable to non-controlling interests arising from the transfer of shares in Daiichi Sankyo Healthcare.
One-off expenses of ¥152,974 million, including compensation for losses incurred by contract manufacturers.
| Item | Details |
|---|---|
| Net Sales | Not disclosed → ¥2,280,000 million |
| Operating profit | Not disclosed → ¥315,000 million |
| Profit attributable to owners of the parent | Not disclosed → ¥260,000 million |
| Net income per share | Not disclosed → 142.88 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Previous-period results | Fiscal year ended March 2026: revenue ¥2,123,045 million, operating profit ¥229,089 million, profit for the year ¥259,874 million, and profit for the year attributable to owners of the parent ¥259,874 million |
| Reason for the revision | The forecast incorporates expected growth in Enhertu and Datroway sales and an increase in gross profit from an improvement in the cost-of-sales ratio, as well as higher expenses due to increased profit-share payments to AstraZeneca and other factors, core and non-core income and expenses, finance income and expenses, income taxes and other taxes, and profit for the year attributable to non-controlling interests arising from the transfer of shares in Daiichi Sankyo Healthcare. |
| Details and amount of extraordinary loss | One-off expenses of ¥152,974 million, including compensation for losses incurred by contract manufacturers. |
| Dividend forecast revision | The forecast for the annual dividend for the fiscal year ending March 2027 has been set at ¥100 (¥50 interim and ¥50 year-end), an increase of ¥22 from the annual dividend of ¥78 for the fiscal year ended March 2026. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased for the fiscal year ended March 2026, owing to growth in Enhertu and Datroway sales and the positive impact of yen depreciation. Operating profit declined because compensation for losses incurred by contract manufacturers and other items were recorded as one-off expenses. For the fiscal year ending March 2027, the Company expects gross profit to increase due to growth in Enhertu and Datroway sales and an improvement in the cost-of-sales ratio, while also anticipating higher expenses, including profit-share payments to AstraZeneca.